IRS Form 8937
This document, Form 8937 and the information contained herein are being provided pursuant to the requirements of Section 6045B of the Internal Revenue Code of 1986, as amended (the “code”), and includes a general summary regarding the application of certain U.S. federal income tax laws and regulations relating to the effects of the Reverse Stock Split (as defined below) on the tax basis of Ritter Pharmaceuticals, Inc. (“Ritter”) stock. The information contained herein does not constitute tax advice and does not purport to be complete or to describe the consequences that may apply to particular categories of stockholders. Ritter does not provide tax advice to its stockholders. You are urged to consult your own tax advisor regarding the particular consequences of the Reverse Stock Split to you, including the applicability and effect of all U.S. federal, state and local and foreign tax laws. We urge you to read the proxy statement on Schedule 14A filed with the Securities and Exchange Commission on December 1, 2017 (the “Proxy Statement”), noting especially the discussion on pages 13 and 14 therein under the heading “Certain U.S. Federal Income Tax Consequences of the Reverse Stock Split”. You may access the Proxy Statement at www.sec.gov .